louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03015376: Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Official title: Cohort Study on Characters and Distribution of Inherited Susceptible Genes Among Epithelial Ovarian Cancer Patients and Their Relatives in the North of China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ovarian Neoplasm Epithelial
Hereditary Breast and Ovarian Cancer Syndrome
Keywords: epithelial ovarian cancer
Hereditary Breast and Ovarian Cancer Syndrome
next-generation sequencing
High-Throughput Nucleotide Sequencing
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2017-01-10
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patiens with epithelia ovarian cancer and their relatves in the North of China

Brief summary: Purpose: To investigate the prevalence of the germline mutations in the BRCA 1/2 and mismatch repair genes in patients with epithelial ovarian cancer (EOC) and their relatives, and related somatic mutations in tumor tissues in the northern part of china.

Patients and methods: A multicenter prospective study will be hold in the northern part of china form 2017. About 1000 female patients with epithelial ovarian cancer and their ralatives will be tested for germline mutations in the BRCA 1/2 and mismatch repair genes and related somatic mutations in tumor tissues, regardless of the family history.

Study type: Observational Official title: Prevalence study of germline mutations in susceptibility ovarian cancer genes in patients with epithelial ovarian cancer and somatic mutations in their tumor tissures in the northern part of china.

Enrollment: 1000


Eligibility criteria: Inclusion Criteria:

1. epithelial ovarian cancer and their relatves
2. living in the north of Huaihe River in China
3. being Han Chinese

Exclusion Criteria:

1. non-epithelial ovarian cancer
2. without specific pathological diagnosis
3. non-Han Chinese

Primary outcomes:
measure: herited gene mutations susceptible to epithelial ovarian cancer in patients and their relatives
timeFrame: two years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Lei Li
state: Beijing
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Wu Ming, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Li W, Shao D, Li L, Wu M, Ma S, Tan X, Zhong S, Guo F, Wang Z, Ye M. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. J Ovarian Res. 2019 Aug 31;12(1):80. doi: 10.1186/s13048-019-0560-y.
citation: Li L, Ma S, Tan X, Zhong S, Wu M. The Urodynamics and Survival Outcomes of Different Methods of Dissecting the Inferior Hypogastric Plexus in Laparoscopic Nerve-Sparing Radical Hysterectomy of Type C: A Randomized Controlled Study. Ann Surg Oncol. 2019 May;26(5):1560-1568. doi: 10.1245/s10434-019-07228-8. Epub 2019 Feb 13.
Clinical trial NCT03834376: Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection
Official title: Pimodivir (JNJ-63623872) Pre Approval Access_Single Patient Access (SPR) for Patients Diagnosed With H7N9 Influenza A Infection
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: H7N9 Subtype of Influenza A Virus
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2019-02-08
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection. Pre-approval access pertains to provision for therapeutic use of an investigational product prior to its marketing authorization. Such access may be considered for eligible patients with serious/life-threatening diseases or conditions, where alternative treatments do not exist or have been exhausted.


Eligibility criteria: Inclusion Criteria:

* The patient has an H7N9 Influenza A infection
* The patient has no known severe hepatic impairment

Exclusion Criteria:

- Any other Influenza A sub-strains other than H7N9

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02518776: Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Multiple Sclerosis
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2015-08-10
Enrollment: 80
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system responsible for physical disability but can also cause cognitive disturbances annoying social and professional life of patients with the disease. Various studies have shown that there was a breach of episodic memory, working memory, attention and executive functions regardless of the form of disease, disability or duration of disease progression.

The main objective of this study is to investigate the influence of emotional components and executive processes on the components retrograde and anterograde episodic memory (thanks to an original paradigm based on the emotional valence of the memory) in MS patients


Eligibility criteria: Inclusion Criteria:

* Men and women 30-60 years of age
* Definite MS (McDonald criteria revised in 2005)
* EDSS \<6
* Sick Shapes: Relapsing multiple sclerosis, Primary progressive multiple sclerosis
* All durations evolution
* French Mother tongue
* Signature of informed consent

Exclusion Criteria:

* Other neurological conditions, previous psychiatric or developmental diagnosis of MS
* Head injury sequelae
* Chronic alcohol or drugs Taking
* EDSS greater than or equal to 6
* Secondary Progressive Form
* Push and / or treatment with corticosteroids within one month
* Treatments Amantadine, Modafinil introduced for less than 3 months
* Patient Trust
* Cognitive Assessment of less than one year (including in particular all or part of the balance sheet proposed in this project)
* Any visual motor deficit or incompatible with the award of cognitive tests
* For women, pregnancy, breastfeeding and / or lack of contraception (a pregnancy test will be done before the PET scan)
* Patient with indications against MRI

Primary outcomes:
measure: anterograde episodic memory: 3 scores of emotional ESR
timeFrame: baseline
measure: retrograde episodic memory: 9 scores TEMP emotional
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: Department of Neurologie, Caen Hospital University
state: Basse-Normandie
Study officials:
References:
Clinical trial NCT00640276: Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome
Official title: A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypercholesterolemia
Metabolic Syndrome
Keywords: pitavastatin
metabolic syndrome
metabolic syndrome risk score
hypercholesterolemia
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2008-03-21
Enrollment: 187
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We will identify the influence of long-term treatment of Pitavastatin compared to non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic syndrome component score. And we will additionally observe the changes of CVD risk factors like lipid profile, abdominal fat, insulin resistance and so on.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 18 and 75
* Patients with LDL ≥ 100mg/dL
* Patients with metabolic syndrome

  1. IFG: Fasting glucose ≥ 100mg/dL
  2. Abdominal Obesity: Waist circumference: men≥90cm,women≥85cm
  3. 1 or more of the following

     1. Triglyceride ≥ 150mg/dL
     2. HDL-C: men \< 40mg/dL, women \< 50mg/dL
     3. Blood pressure: SBP ≥ 130mmHg or DBP ≥ 85mmHg or subject receiving anti-hypertensive treatment

Exclusion Criteria:

* uncontrolled hypertension (DBP ≥ 95mmHg)
* taking diabetic drugs or with HbA1c \> 8%
* LDL ≥ 190mg/dL or Triglyceride ≥ 400mg/dL
* coronary heart disease or other diseases caused by artherosclerosis
* malignancy within 6 months
* Serum creatinine ≥ 2.0mg/dL
* ALT or AST ≥ ULN\*2.5
* CPK ≥ ULN\*2
* hypothyroidism

Primary outcomes:
measure: A change of metabolic syndrome risk component
timeFrame: 48week
Secondary outcomes:
measure: Changes of cardiometabolic profiles : lipid profiles, hs-CRP, adiponectin, HMW adiponectin
timeFrame: 48week
measure: Changes of abdominal visceral fat
timeFrame: 48week
measure: Changes of insulin resistance : OGTT(75g), HOMA
timeFrame: 48week
Other outcomes:
Locations:
city: Bundang-gu
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
city: Guri-si
country: Korea, Republic of
facility: Hanyang Univ. Guri Hospital
state: Gyeonggi-do
Study officials:
affiliation: Hanyang Univ. Guri Hospital
name: Chang Beom Lee
role: STUDY_CHAIR
affiliation: Seoul National University Bundang Hospital
name: Hak Chul Jang
role: STUDY_CHAIR
References:
Clinical trial NCT01980576: Qualitative Pain Measurement at Patients With Degenerative Low Back Pain
Official title: Qualitative Pain Measurement and Sensitization at Patients With Degenerative Low Back Pain With Indication for Lumbar Intervertebral Disc
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Degeneration of Lumbar Intervertebral Disc
Keywords: Pain
Sensitization
Spondylitis
Lead sponsor: Northern Orthopaedic Division, Denmark
Sponsor class: OTHER
First posted: 2013-11-11
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary care clinic.

Brief summary: The purpose of the study is:

* to measure sensitization of the nociceptive system at patients with low back pain in order to carry out a necessary surgical procedure
* to examine a possible association between low back pain and degenerative changes
* to analyse if low back pain is related to the clinical result 6 months after surgery
* to set up a model for pre-operative measurement of pain.


Eligibility criteria: Inclusion Criteria:

* patients who are going to be treated surgically for spondylitis
* ability to understand Danish in order to filling in a questionnaire
* a written signed statement of consent

Exclusion Criteria:

* removal of implants
* diabetic neuropathy or another neuropathic disease
* neurological diseases
* unability to read or understand Danish

Primary outcomes:
measure: Pain measured at lumbar area, hip and ankle by an algometer
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University Hospital
state: Region of Northern Jutland
Study officials:
affiliation: Aalborg University Hospital, Denmark
name: Sten Rasmussen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02005276: Way to Be Active 2 (Lotteries)
Official title: A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Lottery Incentives
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sedentary Employees
Keywords: Sedentary
Behavioral Economic Intervention
Team Studies
Financial Incentives
Workplace Wellness
Team Incentives
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2013-12-09
Enrollment: 209
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Employers are increasingly looking for opportunities to motivate sedentary employees to become more physically active. Workplace walking programs have had mixed success and typically show most improvement among participants that are already fairly active at a baseline. The goal of this study is to determine whether a financial incentive program can motivate sedentary employees to increase the number of steps they walk per day to meet a minimum threshold.

Our primary outcome measure is the proportion of days a minimum activity of 7000 steps or more is achieved. We will assess outcomes each week for 3 months using incentives followed by 3 months of follow-up without incentives. Secondary outcomes will include the average steps walked per day.


Eligibility criteria: Inclusion Criteria:

* 1. We will use a minimum age of 18 to ensure all individuals are legally able to consent.
* 2. Participant will need an iPhone or Android smartphone to be able to use the Moves App for tracking steps

Exclusion Criteria:

* Conditions that would make participation infeasible: 1a. Inability to consent 1b. Illiteracy and/or inability to speak, read, and write English 1c. Participation in another research study 2. Conditions that would make participation unsafe: 2a. Current treatment for drug or alcohol use 2b. Consumption of at least 5 alcoholic drinks per day 2c. Myocardial infarction or stroke within the past 6 months 2d. Current addiction to prescription medicines or street drugs 2e. Serious psychiatric diagnoses (e.g., severe major depressive disorder, bipolar disorder, schizophrenia) 2f. Pregnant or currently breastfeeding 2g. Metastatic cancer 2h. Unstable medical conditions that would likely prevent the participant from completing the study

Primary outcomes:
measure: Proportion of Days a Minimum Activity of 7000 Steps or More is Achieved During Intervention
timeFrame: End of study- 6 months of after enrollment
Secondary outcomes:
measure: Average Number of Steps Per Day During Intervention
timeFrame: End of study- 6 months after enrollment
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Kevin M Volpp, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06345976: Functional Impairment in Albinism
Official title: Functional Impairment in Albinism
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Albinism, Ocular
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2024-04-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be identified in the hospital's database, or may be contacted by patient associations.

Brief summary: Albinism is a genetic and hereditary anomaly that affects pigmentation. This pathology is characterized by a deficit in melanin production. In humans, the clinical diagnosis of albinism is based on a number of factors, including :

* In the integumentary region: fair skin tone, with white hair, eyelashes and eyebrows.
* Ophthalmological: reduced visual acuity, photophobia, nystagmus, transilluminated blue irises, hypopigmentation of the retina at the back of the eye with fovea plana.

As treatment options begin to emerge for certain albinism-induced anomalies (including, for example, the depigmentation that causes photophobia), it is desirable to understand what these patients' complaints are, and to gather their views on the emergence of treatments targeting just one of their complaints, namely glare.


Eligibility criteria: Inclusion Criteria:

* All patients with albinism
* Patients \> 18 years of age
* Non-opposition to study participation

Exclusion Criteria:

No diagnosis according to Kruijt et al. criteria Impossibility (visual, technological) of completing questionnaire

Primary outcomes:
measure: To determine whether patients with albinism would be interested in a treatment that could improve their glare without improving their visual acuity.
timeFrame: Day0
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Fondation A. de Rothschild
Study officials:
References:
Clinical trial NCT04467476: Effects of tDCS on Anaerobic Power of Lower Limb Muscles
Official title: Effects of tDCS on Mechanical Power of the Leg Extensor Muscles of Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Healthy Volunteers
Lead sponsor: Universidade Federal do Piauí
Sponsor class: OTHER
First posted: 2020-07-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Anaerobic power and capacity are essential in many human activities, especially during sports practice that demand a high strength and power of the limbs. Transcranial direct current stimulation is a noninvasive technique that can modulate motor brain areas involved in motor functions and has the potential to optimize muscle capacity. However, their effects on mechanical power are lacking.

This study aims to investigate the effects of transcranial direct current stimulation (tDCS) on mechanical power in healthy subjects.

Detailed description: In this study, a randomized, crossover, double-blind, placebo-controlled experimental design will be used. The 50 participants will be randomized into two groups: (1) Anodal tDCS(real) and (2) Sham tDCS. A single session of anodal and sham tDCS will be performed on each task (pre and post-jump test).

All evaluations will be performed by a single researcher who, like the participants, will not know which stimulation group will be participating. Subjects who agree to the conditions and sign the consent form may participate in the study. Participants who meet the eligibility criteria will be included in the study.

Eligibility criteria: Inclusion Criteria:

* Healthy subjects with no complaints of pain or any kind of discomfort in the musculoskeletal system

Exclusion Criteria:

* Musculoskeletal or neurological disorder
* Under medication
* Previous treatment with tDCS

Primary outcomes:
measure: Mean anaerobic power
timeFrame: Pre and Post-test (immediately after tDCS)
Secondary outcomes:
measure: Peak anaerobic power
timeFrame: Pre and Post-test (immediately after tDCS)
measure: Fatigue index
timeFrame: Pre and Post-test (immediately after tDCS)
measure: Rating of perceived exertion
timeFrame: Post-test (immediately after tDCS)
Other outcomes:
Locations:
city: Parnaíba
country: Brazil
facility: Department of Physical Therapy. Federal University of Piaui
state: Piauí
Study officials:
affiliation: Department of Physical Therapy. Federal University of Piaui
name: Fuas A Hazime, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03838276: RYGB AL 150cm BPL 100cm vs RYGB AL 100cc BPL 150cm
Official title: Ponderal Outcomes After Roux-en-Y Gastric Bypass With Alimentary Limb (AL) of 150cm and Biliopancreatic Limb (BPL) of 100cm vs AL 100cm and BPL 150cm
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Weight Loss
Lead sponsor: Hospital General Universitario Elche
Sponsor class: OTHER
First posted: 2019-02-12
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Roux-en-Y gastric bypass will be performed in all the cases. Patients will be randomized according the limb lengths:

* Group 1: Alimentary limb (AL) 150cm and biliopancreatic limb (BPL) 100cm
* Group 2: AL 100cm and BPL 150cm

Weight loss will be evaluated 1 year after surgery

Detailed description: A Roux-en-Y gastric bypass will be performed in all the cases. Patients will be randomized according the limb lengths:

* Group 1: Alimentary limb 150cm and biliopancreatic limb 100cm
* Group 2: Alimentary limb 100cm and biliopancreatic limb 150cm

Weight loss will be evaluated 1 year after surgery

Eligibility criteria: Inclusion Criteria:

* BMI \> 40 Kg/m2
* BMI \> 35 Kg/m2, associated with obesity-related comorbidities
* Patients undergoing Roux-en-Y gastric bypass as bariatric procedure

Exclusion Criteria:

* Patients undergoing Roux-en-Y gastric bypass as revisional procedure
* Patients lost to follow-up

Primary outcomes:
measure: Weight loss
timeFrame: 1 year after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hospital La PLata
name: Santiago de Battista
role: STUDY_CHAIR
References:
Clinical trial NCT06950476: ART Cycle Outcomes When Only 1 to 3 Oocytes Are Retrieved
Official title: Assisted Reproductive Technology Cycle Outcomes When Only 1 to 3 Oocytes Are Retrieved: a Retrospective Analysis of 3,671 Cycles in Poor Responders From a Large Volume Single Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility Assisted Reproductive Technology
Oocyte Retrieval
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2025-04-30
Enrollment: 3761
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study sample will include all patients registered in the Humanitas Fertility Center database between January 2010 and December 2023, matching the inclusion and exclusion criteria cited above.

Brief summary: This is a monocentric retrospective observational study. The study focuses on the women who underwent Assisted Reproductive Technology (ART) cycles with poor ovarian response (POR), defined as \<4 oocytes retrieved.

The objectives of the study are as follows:

* Evaluate clinical pregnancy rate (CPR) and cumulative live birth rate (CLBR) in women with poor ovarian response.
* Evaluate abortion rate in women with poor ovarian response.
* Evaluate the influence of patient characteristics (age, Anti-Müllerian hormone \[AMH\] levels, Antral Follicle Count \[AFC\], Follicle Stimulating Hormone \[FSH\], Body Mass Index \[BMI\]) on women with poor ovarian response.

To address the study objectives, data will be collected using a specific internal web-based database. All oocyte retrieval procedures performed at the Humanitas Fertility Center from January 2010 to December 2023 will be included in the evaluation. Outcomes will be expressed in terms of CLBR, CPR and Abortion Rate.


Eligibility criteria: Inclusion Criteria:

* The study database will include all women who underwent IVF treatment between 2010 and 2023 and were classified as poor ovarian responders, defined as those who retrieved fewer than 4 oocytes following controlled ovarian stimulation.

Exclusion Criteria:

* The study database will exclude women who underwent IVF treatment and retrieved more than 3 oocytes following controlled ovarian stimulation.

Primary outcomes:
measure: Clinical Pregnancy Rate (CPR)
timeFrame: January 2010 - December 2023
measure: Cumulative Live Birth Rate (CLBR)
timeFrame: January 2010 - December 2023
measure: Abortion Rate
timeFrame: January 2010 - December 2023
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: